Neue Entwicklungen zur Genetik und Therapie des Retinoblastoms

Zusammenfassung

Retinoblastome sind die häufigsten primären intraokularen malignen Tumoren. Etablierte und neue Methoden haben die Chance, dass ein Kind mit einem Retinoblastom nicht nur sein Tumorleiden überlebt, sondern auch eine nutzbare visuelle Funktion behält, erheblich verbessert. Neue Methoden, wie die immer noch experimentelle intraarterielle Chemotherapie, deren Langzeiteffekte noch nicht sicher absehbar sind, haben dabei das Spektrum der zur Verfügung stehenden Therapieoptionen erheblich erweitert. Der exzellenten Chance in Ländern mit einem entwickelten Gesundheitssystem stehen die schlechten Chancen von Kindern mit Retinoblastomen in Ländern der Dritten Welt gegenüber, deren Verbesserung das Ziel gemeinsamer Anstrengungen sein muss.

Abstract

Retinoblastomas are the most frequent primary malignant intraocular tumours worldwide. Conventional and new treatment modalities have significantly improved the chance for survival and preservation of vision. The armamentarium of treatment modalities has been broadened recently by new techniques like intraarterial chemotherapy, which still has to be considered as experimental since long-term follow-up results are not yet available. The excellent prognosis for retinoblastomas in countries with a well developed health system is contrasted by the miserable prognosis for retinoblastomas in developing countries, which must be changed by a joint effort of all centres.

Schlüsselwörter

Genetik - okuläre Tumoren - Kinderophthalmologie

Key words

genetics - ocular tumours - paediatric ophthalmology

Literatur

• 1 Kivela T. The epidemiological challenge of the most frequent eye cancer: retinoblastoma, an issue of birth and death.  Br J Ophthalmol. 2009;  93 1129-1131
• 2 Lohmann D. Retinoblastoma.  Adv Exp Med Biol. 2010;  685 220-227
• 3 Shields C L, Mashayekhi A, Au A K et al. The International Classification of Retinoblastoma predicts chemoreduction success.  Ophthalmology. 2006;  113 2276-2280
• 4 Abramson D H, Frank C M. Second nonocular tumors in survivors of bilateral retinoblastoma: a possible age effect on radiation-related risk.  Ophthalmology. 1998;  105 573-579 ; discussion 579 – 580
• 5 Schueler A O, Fluhs D, Anastassiou G et al. Beta-ray brachytherapy of retinoblastoma: feasibility of a new small-sized ruthenium-106 plaque.  Ophthalmic Res. 2006;  38 8-12
• 6 Gallie B L, Budning A, DeBoer G et al. Chemotherapy with focal therapy can cure intraocular retinoblastoma without radiotherapy.  Arch Ophthalmol. 1996;  114 1321-1328
• 7 Gombos D S, Kelly A, Coen P G et al. Retinoblastoma treated with primary chemotherapy alone: the significance of tumour size, location, and age.  Br J Ophthalmol. 2002;  86 80-83
• 8 Shields C L, Shields J A. Retinoblastoma management: advances in enucleation, intravenous chemoreduction, and intra-arterial chemotherapy.  Curr Opin Ophthalmol. 2010;  21 203-212
• 9 Shields C L, Ramasubramanian A, Thangappan A et al. Chemoreduction for group E retinoblastoma: comparison of chemoreduction alone versus chemoreduction plus low-dose external radiotherapy in 76 eyes.  Ophthalmology. 2009;  116 544-551
• 10 Reese A B, Hyman G A, Merriam Jr G R et al. The treatment of retinoblastoma by radiation and triethylene melamine.  Am J Ophthalmol. 1957;  43 865-872
• 11 Suzuki S, Kaneko A. Management of intraocular retinoblastoma and ocular prognosis.  Int J Clin Oncol. 2004;  9 1-6
• 12 Yamane T, Kaneko A, Mohri M. The technique of ophthalmic arterial infusion therapy for patients with intraocular retinoblastoma.  Int J Clin Oncol. 2004;  9 69-73
• 13 Inomata M, Kaneko A. Chemosensitivity profiles of primary and cultured human retinoblastoma cells in a human tumor clonogenic assay.  Jpn J Cancer Res. 1987;  78 858-868
• 14 Abramson D H, Dunkel I J, Brodie S E et al. A phase I/II study of direct intraarterial (ophthalmic artery) chemotherapy with melphalan for intraocular retinoblastoma initial results.  Ophthalmology. 2008;  115 1398-1404, 1404 e1391
• 15 Abramson D H, Dunkel I J, Brodie S E et al. Bilateral superselective ophthalmic artery chemotherapy for bilateral retinoblastoma: tandem therapy.  Arch Ophthalmol. 2010;  128 370-372
• 16 Gobin Y P, Dunkel I J, Marr B P et al. Intra-arterial Chemotherapy for the Management of Retinoblastoma: Four-Year Experience.  Arch Ophthalmol. 2011;  online first
• 17 Marr B, Gobin P Y, Dunkel I J et al. Spontaneously Resolving Periocular Erythema and Ciliary Madarosis Following Intra-arterial Chemotherapy for Retinoblastoma.  Middle East Afr J Ophthalmol. 2010;  17 207-209
• 18 Abramson D H, Dunkel I J, Brodie S E et al. Superselective Ophthalmic Artery Chemotherapy as Primary Treatment for Retinoblastoma (Chemosurgery).  Ophthalmology. 2010;  117 1623-1629
• 19 Abramson D H. Super selective ophthalmic artery delivery of chemotherapy for intraocular retinoblastoma: ‘chemosurgery’ the first Stallard lecture.  Br J Ophthalmol. 2010;  94 396-399
• 20 Vajzovic L M, Murray T G, Aziz-Sultan M A et al. Supraselective intra-arterial chemotherapy: evaluation of treatment-related complications in advanced retinoblastoma.  Clin Ophthalmol. 2011;  5 171-176
• 21 Shields C L, Bianciotto C G, Jabbour P et al. Intra-arterial Chemotherapy for Retinoblastoma: Report No. 1, Control of Retinal Tumors, Subretinal Seeds, and Vitreous Seeds.  Arch Ophthalmol. 2011;  online first
• 22 Shields C L, Bianciotto C G, Jabbour P et al. Intra-arterial Chemotherapy for Retinoblastoma: Report No. 2, Treatment Complications.  Arch Ophthalmol. 2011;  online first
• 23 Munier F L, Beck-Popovic M, Balmer A et al. Occurrence of sectoral choroidal occlusive vasculopathy and retinal arteriolar embolization after superselective ophthalmic artery chemotherapy for advanced intraocular retinoblastoma.  Retina. 2011;  31 566-573
• 24 Vajzovic L M, Murray T G, Aziz-Sultan M A et al. Clinicopathologic review of enucleated eyes after intra-arterial chemotherapy with melphalan for advanced retinoblastoma.  Arch Ophthalmol. 2010;  128 1619-1623
• 25 Aziz H A, Boutrid H, Murray T G et al. Supraselective injection of intraarterial melphalan as the primary treatment for late presentation unilateral multifocal stage Vb retinoblastoma.  Retina. 2010;  30 S63-S65
• 26 Abramson D H, Frank C M, Dunkel I J. A phase I/II study of subconjunctival carboplatin for intraocular retinoblastoma.  Ophthalmology. 1999;  106 1947-1950
• 27 Murray T G, Cicciarelli N, O’Brien J M et al. Subconjunctival carboplatin therapy and cryotherapy in the treatment of transgenic murine retinoblastoma.  Arch Ophthalmol. 1997;  115 1286-1290
• 28 Schmack I, Hubbard G B, Kang S J et al. Ischemic necrosis and atrophy of the optic nerve after periocular carboplatin injection for intraocular retinoblastoma.  Am J Ophthalmol. 2006;  142 310-315
• 29 Kiratli H, Kocabeyoglu S, Bilgic S. Severe pseudo-preseptal cellulitis following sub-Tenon’s carboplatin injection for intraocular retinoblastoma.  J AAPOS. 2007;  11 404-405
• 30 Chantada G L, Fandino A C, Carcaboso A M et al. A phase I study of periocular topotecan in children with intraocular retinoblastoma.  Invest Ophthalmol Vis Sci. 2009;  50 1492-1496
• 31 Mallipatna A C, Dimaras H, Chan H S et al. Periocular topotecan for intraocular retinoblastoma.  Arch Ophthalmol. 2011;  129 738-745
• 32 Kaneko A, Suzuki S. Eye-preservation treatment of retinoblastoma with vitreous seeding.  Jpn J Clin Oncol. 2003;  33 601-607
• 33 Seregard S, Kock E, af T rampe E. Intravitreal chemotherapy for recurrent retinoblastoma in an only eye (letter).  Br J Ophthalmol. 1995;  79 194-195
• 34 Frenkel S, Hendler K, Siegal T et al. Intravitreal methotrexate for treating vitreoretinal lymphoma: 10 years of experience.  Br J Ophthalmol. 2008;  92 383-388
• 35 Kivela T, Eskelin S, Lindahl P et al. Intravitreal methotrexate monotherapy as salvage treatment for recurrent retinoblastoma after standard chemoreduction. In, Meeting of the International Society of Ocular Oncology Cambridge; 2009